Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Expert Explains Effect of Age and Gender on Outcomes in RCC

May 21st 2020

Rana R. McKay, MD, sheds light on the impact of age and gender on the outcomes of patients with RCC, the implications of clinical determinants on toxicity, and where future research efforts will focus.

Expert Explains Effect of Age and Gender on Outcomes in RCC

May 21st 2020

Rana R. McKay, MD, sheds light on the impact of age and gender on the outcomes of patients with RCC, the implications of clinical determinants on toxicity, and where future research efforts will focus.

ASCO 2020: Top KOLs Select Vital Studies Ahead of Virtual Meeting

May 21st 2020

Ahead of the 2020 ASCO Virtual Scientific Program, we spoke with a handful of leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their respective specialties.

Tivozanib's Safety Profile Linked With Advantage in Advanced RCC Treatment

May 20th 2020

Brian I. Rini, MD, speaks about the TIVO-3 trial and how its results could provide patients with another “weapon in this disease.”

Dr. Subbiah on the Utility of Tivozanib in RCC

May 20th 2020

Vivek Subbiah, MD, discusses the utility of tivozanib in renal cell carcinoma.

Low-Intensity Surveillance Demonstrates Utility in NMIBC

May 20th 2020

Low-intensity surveillance may be comparable to high-intensity surveillance for cancer control in patients with high-risk non-muscle invasive bladder cancer.

Low-Intensity Surveillance Demonstrates Utility in NMIBC

May 19th 2020

Patients who had low-intensity cystoscopy surveillance underwent fewer transurethral resections but did not experience an increased risk of progression or bladder cancer death compared with those who had high-intensity surveillance.

Dr. Tsao on Improving Outcomes in RCC

May 16th 2020

Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.

Dr. Tsao on Improving Outcomes in RCC

May 15th 2020

Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.

Dr. Iyer on TRAEs With Erdafitinib in Urothelial Cancer

May 14th 2020

Gopa Iyer, MD, discusses treatment-related adverse events (TRAEs) with erdafitinib (Balversa) in urothelial cancer.

Dr. Sfakianos on Importance of Restaging Transurethral Resection of Bladder Tumors

May 13th 2020

John P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.

Dr. Sfakianos on Importance of Restaging Transurethral Resection of Bladder Tumors

May 12th 2020

John P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.

Choueiri Spotlights Activity With Novel HIF-2a Inhibitor in Heavily Pretreated RCC

May 12th 2020

Toni K. Choueiri, MD, discusses the findings from the phase 1/2 trial, the clinical implications of targeting HIF-2α in kidney cancer, and the potential utility of MK-6482 in clear cell RCC.

Choueiri Spotlights Activity With Novel HIF-2α Inhibitor in Heavily Pretreated RCC

May 12th 2020

Toni K. Choueiri, MD, discusses the findings from the phase 1/2 trial, the clinical implications of targeting HIF-2α in kidney cancer, and the potential utility of MK-6482 in clear cell RCC. 

Dr. Lee on Second-Line Treatment Options in RCC

May 12th 2020

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

Dr. Powles on the 42-Month Follow-Up Data From the CheckMate-214 Trial in RCC

May 2nd 2020

Thomas Powles, MD, MBBS, MRCP, director, Barts Cancer Institute, discusses the 42-month follow-up data from the phase 3 CheckMate-214 trial in advanced renal cell carcinoma (RCC).

Dr. Petrylak on the Results of the EV-103 Trial in Bladder Cancer

May 1st 2020

Daniel P. Petrylak, MD, professor of medicine and urology, co-leader, Cancer Signaling Networks, Yale Cancer Center, and 2017 Giant of Cancer Care® in Genitourinary Cancers, discusses the results of the phase 1b/2 EV-103 trial in bladder cancer.

Long-Term Data Show Nivolumab/Ipilimumab as Preferred Frontline Regimen in RCC

April 30th 2020

Nizar M. Tannir, MD, FACP, discusses the 42-month follow-up results from the CheckMate-214 trial in advanced renal cell carcinoma and provides perspective on other approved combinations in the frontline setting.

New Therapeutic Era Sparks Fresh Questions About Nephrectomy in RCC

April 25th 2020

Although fewer patients are undergoing cytoreductive nephrectomy as systemic treatments for renal cell carcinoma improve, the modality still has a vital role to play in the treatment paradigm—even in the modern age of immune checkpoint inhibitors.

Dr. Grivas on the Future of Molecular Subtyping in Urothelial Cancer

April 23rd 2020

Petros Grivas, MD, PhD, discusses the future of molecular subtyping in urothelial cancer.

NEXT PAGE
PREVIOUS PAGE